Anavex Life Sciences Corp. (AVXL)

Anavex Life Sciences Ratios and Metrics

Market cap in millions USD. Fiscal year is October - September.

Year Ending	Current	Sep 30, 2023	Sep 30, 2022	Sep 30, 2021	Sep 30, 2020	Sep 30, 2019
Market Capitalization	479	537	804	1,359	274	166
Market Cap Growth	-37.50%	-33.27%	-40.81%	396.21%	64.61%	34.14%
Enterprise Value	324	386	655	1,207	245	144
PE Ratio	-	-11.30	-16.76	-35.85	-10.42	-6.33
PB Ratio	3.44	3.78	5.65	9.01	10.06	8.20
P/FCF Ratio	-12.87	-19.32	-33.19	-44.73	-12.87	-8.98
P/OCF Ratio	-12.87	-19.32	-33.19	-44.73	-12.87	-8.98
EV/EBITDA Ratio	-6.89	-8.12	-13.76	-32.06	-9.32	-5.50
EV/EBIT Ratio	-6.89	-8.12	-13.76	-32.06	-9.32	-5.50
EV/FCF Ratio	-8.58	-13.88	-27.03	-39.72	-11.49	-7.78
Quick Ratio	14.58	12.05	14.60	14.09	4.00	4.40
Current Ratio	15.12	12.32	14.95	14.97	4.73	5.03
Return on Equity (ROE)	-29.00%	-33.40%	-32.40%	-35.30%	-102.40%	-151.70%
Return on Assets (ROA)	-26.80%	-30.70%	-30.50%	-32.50%	-81.70%	-116.90%
Return on Capital (ROIC)	-37.04%	-39.31%	-35.78%	-27.85%	-114.14%	-143.46%
Earnings Yield	-8.75%	-8.85%	-5.96%	-2.79%	-9.60%	-15.80%
FCF Yield	-7.00%	-5.18%	-3.01%	-2.24%	-7.77%	-11.14%
Buyback Yield / Dilution	-5.31%	-3.74%	-10.18%	-19.95%	-18.99%	-9.52%
Total Shareholder Return	-5.31%	-3.74%	-10.18%	-19.95%	-18.99%	-9.52%

Source: Financials are provided by Nasdaq Data Link and sourced from the audited annual (10-K) and quarterly (10-Q) reports submitted to the Securities and Exchange Commission (SEC).